LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
- 252 Downloads
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar® (EU); Basaglar® (USA)] has been approved in the EU as a biosimilar to reference insulin glargine (Lantus®), and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes. Structural and functional characterization of LY insulin glargine in preclinical studies showed that it is similar to reference insulin glargine. In phase I euglycaemic clamp studies, LY insulin glargine demonstrated similar pharmacodynamic (including duration of action) and pharmacokinetic parameters to reference insulin glargine. In the phase III ELEMENT trials, LY insulin glargine and reference insulin glargine were noninferior to each other with respect to glycaemic control, indicating their equivalent efficacy, when administered with mealtime insulin in adults with type 1 diabetes or with oral antiglycaemic medications in adults with type 2 diabetes. LY insulin glargine was generally well tolerated, with a safety profile (including the risk of hypoglycaemia and immunogenicity) similar to that of reference insulin glargine and without any additional safety concerns identified. Basal insulin treatment status at baseline did not impact the relative efficacy, safety and immunogenicity of LY insulin glargine versus reference insulin glargine in the ELEMENT 1 and 2 trials. In conclusion, LY insulin glargine offers an additional basal insulin option for patients with type 1 or 2 diabetes, potentially at a lower cost.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Yvette Lamb and Yahiya Syed are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/FF98F0603768E31C.
- 1.International Diabetes Federation. Diabetes and cardiovascular disease: executive summary. 2016. http://www.idf.org/. Accessed 9 Jan 2018.
- 5.Eli Lilly and Company. US prescribing information for Basaglar (insulin glargine injection), for subcutaneous use. 2016. http://pi.lilly.com/. Accessed 9 Jan 2018.
- 6.US FDA. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes [media release]. 16 Dec 2015. http://www.fda.gov/.
- 7.European Medicines Agency. Abasaglar (previously Abasria): summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 9 Jan 2018.
- 8.European Medicines Agency. Abasria CHMP assessment report. 2014. http://www.ema.europa.eu/. Accessed 9 Jan 2018.
- 10.Pollom RK, Lacaya LB, Ilag LL. Efficacy and safety between insulin glargine products (LY293016 and Lantus®) in patients with T2DM: the ELEMENT 5 study [abstract no. 963-P]. In: American Diabetes Association 77th Scientific Sessions. 2017.Google Scholar
- 11.Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734–41.CrossRefPubMedGoogle Scholar
- 12.Eli Lilly and Company. A study of LY2963016 compared to Lantus® in adult participants with type 2 diabetes mellitus (ELEMENT 5) [ClinicalTrials.gov identifier NCT02302716] US National Institutes of Health, ClinicalTrials.gov. 2017. http://clinicaltrials.gov/. Accessed 9 Jan 2018.
- 13.Perez-Nieves M, Pollom RK, Delozier AM, et al. Adult low blood sugar survey (ALBSS) and insulin treatment satisfaction questionnaire (ITSQ) patient-reported outcomes (pros) in LY2963016 insulin glargine (LY IGlar) and lantus insulin glargine (IGlar) trials [abstract no. 2495-PO]. Diabetes. 2015;64(Suppl 1):A631.Google Scholar
- 15.Takahashi A, Chida D, Nishiyama H. The efficacy and safety of LY2963016 insulin glargine (LY IGlar) in Japanese patients with type 1 diabetes mellitus previously treated with Lantus insulin glargine (IGlar): a subgroup analysis of the ELEMENT-1 study: therapeutics of diabetes [abstract no. 0046]. J Diabetes Investig. 2016;7(Suppl 2):20.Google Scholar
- 18.Eli Lilly and Company. A study in adults with type 1 diabetes (ELEMENT 1) [ClinicalTrials.gov identifier NCT01421147] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/. Accessed 9 Jan 2018.
- 19.Eli Lilly and Company. A study in adults with type 2 diabetes (ELEMENT 2) [ClinicalTrials.gov identifier NCT01421459] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/. Accessed 9 Jan 2018.
- 20.National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. 2016. http://www.nice.org.uk/. Accessed 9 Jan 2018.
- 21.National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2017. http://www.nice.org.uk/. Accessed 9 Jan 2018.
- 23.European Medicines Agency. LUSDANA 100 units/mL solution for injection in a pre-filled pen: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 9 Jan 2018.
- 24.Merck. Merck announces U.S. FDA grants tentative approval for LUSDANA™ Nexvue™ (insulin glargine injection, a follow-on biologic basal insulin [media release]. 20 Jul 2017. http://investors.merck.com/. Accessed 9 Jan 2018.
- 25.American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40(Suppl 1):S1–134.Google Scholar
- 28.Owens RA, Kahl SD, Ruan X, et al. The in vitro pharmacology of LY IGlar (LY2963016): a new insulin glargine product [abstract no. 1033-P]. Diabetes. 2015;64(Suppl 1):A265.Google Scholar
- 32.Guettier J-M. Center for drug evaluation and research: summary review (application number 205692Orig1s000). 2014. http://www.accessdata.fda.gov/. Accessed 9 Jan 2018.
- 33.Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226–33.CrossRefPubMedGoogle Scholar